Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis

28 Sept 2011

Abstract excerpt

Overcoming the resistance of glioblastoma cells against temozolomide, the first-line chemotherapeutic agent of choice for newly diagnosed glioblastoma, is a major therapeutic challenge in the management of this deadly brain tumor. The gene encoding O(6) -methylguanine DNA methyltransferase (MGMT), which removes the methyl group attached by temozolomide, is often silenced by promoter methylation in glioblastoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to MicroRNA in disease regulation
Share to Neurogenesis and neuroplasticity mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21957016
DOI: 10.1002/stem.753

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 AxisPMID 21957016Read ↗

Molecular mechanisms of temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

The MDM2–p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem CellsSemantic proximity Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Potential Strategies Overcoming the Temozolomide Resistance for GlioblastomaSemantic proximity Read ↗

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read ↗

Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemnessSemantic proximity Read ↗

Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastomaSemantic proximity Read ↗

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastomaSemantic proximity Read ↗

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkersSemantic proximity Read ↗

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Semantic proximity Read ↗

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastomaSemantic proximity Read ↗

O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting ConditionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.